摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-methyl-1H-pyrrole-2,5-dicarboxylic acid | 7374-73-4

中文名称
——
中文别名
——
英文名称
1-methyl-1H-pyrrole-2,5-dicarboxylic acid
英文别名
N-methylpyrrole-2,5-dicarboxylic acid;1-methyl-pyrrole-2,5-dicarboxylic acid;1-Methyl-pyrrol-2,5-dicarbonsaeure;1-Methylpyrrole-2,5-dicarboxylic acid
1-methyl-1H-pyrrole-2,5-dicarboxylic acid化学式
CAS
7374-73-4
化学式
C7H7NO4
mdl
——
分子量
169.137
InChiKey
WYFYVYADIQMVAW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    270-275 °C
  • 沸点:
    441.2±30.0 °C(Predicted)
  • 密度:
    1.46±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    79.5
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-methyl-1H-pyrrole-2,5-dicarboxylic acidN,N-二甲基甲酰胺 草酰氯 作用下, 以 四氢呋喃 为溶剂, 反应 4.0h, 生成 1-methyl-1H-pyrrole-2,5-dicarbonyl dichloride
    参考文献:
    名称:
    [EN] C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
    [FR] DIMERES DE C8,C8' 5-OXO-1,2,3, 11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE LIES PAR DES LIEURS D'AMIDE D'ACIDE 1-H-PYRROLE-DICARBOXYLIQUE ET LEURS ANALOGUES OLIGOMERES AINSI QUE DES COMPOSES CONNEXES DESTINES AU TRAITEMENT DE MALADIES PROLIFERATIVES
    摘要:
    公式(I)的化合物:PBD-A-Y-X-(Het)na-L-(Het)nb-L-(Het)nc-T-(Het')nd-L-(Het')ne-L-(Het')nf-X'-Y'-A'-PBD'及其盐、溶剂合物和化学保护形式,其中PBD单位具有化学式(PBD)(PBD'),每个分子的8位置的键分别与A和A'基团结合;A从O、S、NH或单键中选择,每个Het和Het'分别为氨基-杂芳基-羰基基团;X和X'都是NH或C(=O)-Q-C(=O)-,其中Q是二价基团,使得HY = R;在第二方面,本发明涉及一般化学式(II)的化合物:PBD-A-Y-X-(Het)ng-[L-(Het)nh] nj-X'-Y'-A'-PBD'。其中:PBD和PBD'如上所定义,X和X'分别为NH和C(=O)或C(O)和NH;其他取代基在权利要求中定义。本发明的其他方面涉及它们在制造用于治疗增殖性疾病的药物中的用途。
    公开号:
    WO2005085250A1
  • 作为产物:
    参考文献:
    名称:
    [EN] 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT
    [FR] CONJUGUÉS ANTICORPS-MÉDICAMENT DIMÉRIQUE 1-(CHLOROMÉTHYL)-2,3-DIHYDRO-1 H-BENZO [E]INDOLE, ET MÉTHODES D'UTILISATION ET DE TRAITEMENT
    摘要:
    本发明提供了包含通过连接器与1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚(CBI)二聚体药物部分偶联的抗体的抗体药物偶联物,以及使用抗体药物偶联物的方法。
    公开号:
    WO2015023355A1
点击查看最新优质反应信息

文献信息

  • BIFUNCTIONAL CYTOTOXIC AGENTS
    申请人:Pfizer Inc.
    公开号:US20150209445A1
    公开(公告)日:2015-07-30
    Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    细胞毒性二聚体包括基于CBI和/或CPI的亚单位,包括这种二聚体的抗体药物结合物,以及使用它们治疗癌症和其他疾病的方法。
  • MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME
    申请人:TABATA Masayoshi
    公开号:US20110224343A1
    公开(公告)日:2011-09-15
    The present invention provides a modifier for aromatic polyesters which enhances the melt fluidity of aromatic polyesters without a significant decrease in the heat resistance of the aromatic polyesters, and an aromatic polyester resin composition including the modifier for aromatic polyesters. The present invention relates to a modifier for aromatic polyesters comprising polyhydric phenol residues and residues of aromatic polycarboxylic acid, acid halide or acid anhydride thereof, and the modifier comprises a material having a structure composed of a first residue selected from the group consisting of divalent residues represented by Formula (I): —Ar—W 1 x —Ar— and by Formula (II): —Ar—, the first residues being bonded to two identical or different second residues selected from the group consisting of monovalent residues represented by Formula (III): and monovalent residues represented by Formula (IV): —O—C(O)—R 7 —.
    本发明提供了一种用于芳香族聚酯的改性剂,可以增强芳香族聚酯的熔融流动性,而不明显降低芳香族聚酯的耐热性,以及包括该改性剂的芳香族聚酯树脂组合物。本发明涉及一种用于芳香族聚酯的改性剂,包括多羟基酚残基和芳香族多羧酸、酸卤或其酸酐残基,该改性剂包括具有以下结构的材料:第一残基,选择自由式(I)所代表的二价残基:—Ar—W1x—Ar—和自由式(II)所代表的:—Ar—,第一残基与选择自由式(III)所代表的单价残基:和自由式(IV)所代表的单价残基:—O—C(O)—R7—的两个相同或不同的第二残基结合。
  • [EN] C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DIMERES DE C8,C8' 5-OXO-1,2,3, 11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE LIES PAR DES LIEURS D'AMIDE D'ACIDE 1-H-PYRROLE-DICARBOXYLIQUE ET LEURS ANALOGUES OLIGOMERES AINSI QUE DES COMPOSES CONNEXES DESTINES AU TRAITEMENT DE MALADIES PROLIFERATIVES
    申请人:SPIROGEN LTD
    公开号:WO2005085250A1
    公开(公告)日:2005-09-15
    Compounds of formula (I): PBD-A-Y-X- (Het)na-L- (Het)nb-L- (Het)nc-T- (Het')nd-L- (Het')ne-L- (Het')nf-X' -Y' -A' -PBD' and salts, solvates and chemically protected forms thereof, are disclosed wherein the PBD units have the formulae (PBD) (PBD') with the bonds at the 8 position on each molecule bond to the A and A' groups respectively ; A is selected from O, S, NH or a single bond , and each Het and Het' is respectively an amino-heteroarylene-carbonyl group ; X and X' are both either NH or C (=O) -Q-C (=O) - wherein Q is a divalent group such that HY = R ; in a second aspectm the invention comprises compounds of the general formula (II) : PBD-A-Y-X-(Het)ng-[L-(Het)nh] nj-X' -Y' -A' -PBD'. Wherein : PBD and PBD' are as defined above, X and X' are either NH and C(=O) respectively or C(O) and NH respectively ; the other substituents are defined in the claims. Further aspects of the present invention relate to their use in the manufacture of a medicament for the treatment of a proliferative disease.
    公式(I)的化合物:PBD-A-Y-X-(Het)na-L-(Het)nb-L-(Het)nc-T-(Het')nd-L-(Het')ne-L-(Het')nf-X'-Y'-A'-PBD'及其盐、溶剂合物和化学保护形式,其中PBD单位具有化学式(PBD)(PBD'),每个分子的8位置的键分别与A和A'基团结合;A从O、S、NH或单键中选择,每个Het和Het'分别为氨基-杂芳基-羰基基团;X和X'都是NH或C(=O)-Q-C(=O)-,其中Q是二价基团,使得HY = R;在第二方面,本发明涉及一般化学式(II)的化合物:PBD-A-Y-X-(Het)ng-[L-(Het)nh] nj-X'-Y'-A'-PBD'。其中:PBD和PBD'如上所定义,X和X'分别为NH和C(=O)或C(O)和NH;其他取代基在权利要求中定义。本发明的其他方面涉及它们在制造用于治疗增殖性疾病的药物中的用途。
  • Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
    申请人:Fan Hong
    公开号:US20050147555A1
    公开(公告)日:2005-07-07
    Methods for the preparation of multivalent constructs for therapeutic and diagnostic applications are provided. More specifically, novel methods for preparing multivalent constructs comprising the formula A-B-C-D-E-B′-F for therapeutic and diagnostic applications are provided which use a novel linker D comprising, in various embodiments, a dicarboxylic acid derivative such as, e.g., a glutaric acid bis N-hydroxysuccinimidyl ester or a derivative therof; or a diamine derivative. The remaining components in the multivalent construct A-B-C-D-E-B′-F are defined as follows: A is a first peptide, B is a first branching group, C is an optional first spacer, E is an optional second spacer which may be the same as or different from said first spacer C, B′ is an optional second branching group which may be the same as or different from said first branching group B, and F is a second peptide which may be the same as or different from said first peptide A.
    提供了制备用于治疗和诊断应用的多价构建物的方法。更具体地,提供了用于制备多价构建物的新方法,其包括公式A-B-C-D-E-B'-F,其中使用了一种新的连接剂D,该连接剂D包括各种衍生物,例如戊二酸双N-羟基琥珀酰亚胺酯或其衍生物;或者是一种二胺衍生物。多价构建物A-B-C-D-E-B'-F中的其余组分定义如下:A是第一肽,B是第一分支基团,C是可选的第一间隔物,E是可选的第二间隔物,可以与第一间隔物C相同或不同,B'是可选的第二分支基团,可以与第一分支基团B相同或不同,而F是第二肽,可以与第一肽A相同或不同。
  • C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases
    申请人:Howard Wilson Philip
    公开号:US20070191349A1
    公开(公告)日:2007-08-16
    Compounds of formula (I): PBD-A-Y—X—(Het) na -L-(Het) nb -L-(Het) nc -T-(Het′) nd -L-(Het′) ne -L-(Het′) nf —X′—Y′- A′-PBD′ and salts, solvates and chemically protected forms thereof, are disclosed wherein the PBD units have the formulae (PBD) (PBD′) with the bonds at the 8 position on each molecule bond to the A and A′ groups respectively; A is selected from O, S, NH or a single bond, and each Het and Het′ is respectively an amino-heteroarylene-carbonyl group; X and X′ are both either NH or C (═O)-Q—C(═O)— wherein Q is a divalent group such that HY═R; in a second aspectm the invention comprises compounds of the general formula (II): PBD-A-Y—X—(Het) ng -[L-(Het) nh ] nj -X′—Y′-A′-PBD′. Wherein: PBD and PBD′ are as defined above, X and X′ are either NH and C(═O) respectively or C(O) and NH respectively; the other substitutents are defined in the claims. Further aspects of the present invention relate to their use in the manufacture of a medicament for the treatment of a proliferative disease.
    公式(I)的化合物:PBD-A-Y—X—(Het)na-L-(Het)nb-L-(Het)nc-T-(Het′)nd-L-(Het′)ne-L-(Het′)nf—X′—Y′-A′-PBD′及其盐,溶剂化物和化学保护形式,其中PBD单元具有式(PBD)(PBD′),每个分子上8位置的键分别与A和A'基团结合;A选择自O,S,NH或单键,每个Het和Het′分别是氨基杂芳基羰基基团;X和X′均为NH或C(═O)-Q-C(═O)-,其中Q是二价基团,使得HY═R;在第二方面,本发明涉及一般式(II)的化合物:PBD-A-Y—X—(Het)ng-[L-(Het)nh]nj-X′—Y′-A′-PBD′。其中:PBD和PBD′如上所定义,X和X′分别为NH和C(═O)或C(O)和NH;其他取代基在权利要求中定义。本发明的进一步方面涉及它们在制造用于治疗增殖性疾病的药物中的使用。
查看更多